Cipla Q2 Results: Why Profit Fell 35% Despite Strong India Sales

Cipla sold ₹370 crore more medicines in India this September quarter than it did a year ago. But across the entire company, profit fell by ₹473 crore. That is what makes Cipla's Q2 FY27 results worth looking at more closely.

India is growing and overall revenue has barely moved, yet Cipla is earning much less from its sales. The reasons lie in its US product portfolio, rising costs and a pipeline that is still finding its feet.

Cipla Q2 FY27 Results: What Changed in the Numbers?

For the quarter ended September 30, 2026, Cipla reported revenue from operations of ₹7,404 crore, down 2.4% from ₹7,589 crore a year earlier. EBITDA, or operating profit before interest, tax, depreciation and amortisation, declined nearly 27% to ₹1,388 crore. Profit attributable to shareholders fell 35.1% to ₹878 crore.

Source: Cipla Q2 FY27 consolidated financial results and investor presentation, October 27, 2026. Rounded figures. The ₹878 crore profit is attributable to owners of Cipla; total consolidated profit including non-controlling interests was about ₹852 crore.

A year ago, Cipla made about ₹25 in EBITDA for every ₹100 of revenue. This quarter, it made ₹18.70.

There is one accounting detail to keep in mind. Since April 2026, Cipla has shown certain marketing and promotional expenses as deductions from revenue instead of including them in other expenses. This affects the reported revenue comparison but not profit or cash flow. It does not explain the fall in earnings.

Why Cipla's US Business Is Hurting Profitability

A few years ago, Cipla had a lucrative opportunity in the US with generic lenalidomide, the lower-cost version of Revlimid, a drug used to treat blood cancer. When only a limited number of generic manufacturers could sell the drug, the economics were attractive. As more competitors entered, that advantage faded.

Not all medicine sales contribute equally to profit. Losing ₹100 crore from a particularly profitable drug can hurt earnings more than gaining ₹100 crore from a more competitive product.

There has been another setback. Supplies of lanreotide, a medicine sold in the US, were disrupted following regulatory observations at manufacturing partner Pharmathen. Management said during the October 27 earnings call that it does not expect the product to return during FY27. Cipla is pursuing fixes with its existing partner and developing an alternative manufacturing route, but neither provides an immediate recovery.

The regional results show the scale of the problem. North America revenue fell from ₹2,039 crore in Q2 FY26 to ₹1,643 crore in Q2 FY27. That is a decline of ₹396 crore, or 19% in rupee terms. In dollar terms, sales dropped from about $233 million to $172 million.

Cipla has not disclosed the profit lost from either drug individually, so their precise earnings impact cannot be calculated.

Why Did Costs Rise When Revenue Fell?

The US slowdown is only part of the earnings explanation. Cipla's cost structure also became heavier relative to sales.

Revenue fell by about ₹185 crore year-on-year, but EBITDA declined by ₹507 crore. The financial statements help reconcile that difference. Net material and traded-goods costs increased by roughly ₹136 crore, employee expenses rose by around ₹160 crore, and other operating expenses increased by approximately ₹26 crore.

These are company-wide costs, not expenses that can all be attributed to the US. Together, they explain the much larger fall in operating profit.

The company's gross margin also declined from approximately 67.1% to 64.4%. This means less money was left from every ₹100 of sales after covering material and traded-goods costs. A less profitable product mix is consistent with the loss of high-value US sales, although the disclosures do not isolate it as the only cause. Management has also referred to investment in upcoming launches and manufacturing readiness. Higher input and freight costs have created additional pressure in some markets.

Other income fell by ₹118 crore and depreciation and amortisation rose by ₹48 crore, pushing profit before tax lower still.

Research spending was not the culprit. Cipla's R&D expenditure was ₹423 crore this quarter, below the ₹539 crore reported a year earlier. The pressure came from several moving parts, rather than a sudden surge in research costs.

India's Strong Quarter Could Not Replace the Lost US Profit

While the US business struggled, Cipla's India operations delivered their highest quarterly revenue yet. Sales rose 12% to ₹3,516 crore, supported by prescription medicines, trade generics and consumer health products. Growth in chronic therapies such as respiratory, cardiac, urology and diabetes treatments remained an important part of the story.

India added around ₹370 crore in revenue as North America lost ₹396 crore. Domestic growth almost made up for the US decline in sales, but not in profitability.

That distinction is essential. Strong domestic sales are helping Cipla hold its overall revenue base, but they cannot automatically replace the earnings once generated by a limited-competition US product. Cipla does not publish the product-level margin detail needed to compare those contributions exactly.

Yurpeak, Cipla's tirzepatide brand marketed with Eli Lilly, could support further growth in India. That does not guarantee a replacement for lost US profits.

Can Cipla's New US Drugs Bring the Margins Back?

Cipla's US business has already shown a modest improvement from the June quarter. Dollar revenue rose from $162 million in Q1 FY27 to $172 million in Q2. The company now hopes that new respiratory medicines will turn that early improvement into something more substantial.

Generic Ventolin is being scaled up, while generic Advair Diskus, which has received US FDA approval, is scheduled for launch in Q3 FY27. Cipla also has other respiratory and peptide opportunities in development, subject to regulatory clearance and commercial execution.

Management has retained its goal of exiting FY27 at a $1 billion annualised US revenue run-rate. The wording matters. This is not a promise to earn $1 billion during FY27. It means reaching a quarterly sales pace equivalent to roughly $250 million by the end of the year. From the $172 million recorded in Q2, that requires an increase of about 45% in the quarterly revenue pace.

That requires timely launches, reliable manufacturing, customer demand and attractive pricing. Cipla says this target does not depend on lanreotide returning in FY27.

Investors should watch profit margins as closely as sales. EBITDA margin has already improved from 16.7% in Q1 FY27 to 18.7% in Q2, and management continues to guide for 18.5% to 20% for the full year. But even successful launches may not recreate the exceptional profitability Cipla previously enjoyed from some US generics. More revenue is valuable only if enough of it reaches the profit line.

What Do Cipla's Q2 Results Mean for Its Share Price?

Cipla shares closed at ₹1,350 on the NSE on October 27, 2026, down about 0.37% for the day after touching an intraday low of ₹1,319. The closing decline was much smaller than the 35% drop in quarterly profit. That does not make the earnings weakness insignificant. It simply means the market's response cannot be read from the profit figure alone, especially when investors may have anticipated part of the slowdown.

For shareholders, the more useful question is what Cipla's earnings could look like after the next wave of US launches. If Ventolin and Advair add meaningful sales, the company may be able to spread its manufacturing and employee costs over a larger revenue base. Together with India's growth, that could support a recovery in operating margins.

But there is a risk in assuming that every new US generic will be as profitable as the products it replaces. Launch delays, competitive pricing and slower customer adoption could leave Cipla with higher sales but still-disappointing margins. Regulatory and manufacturing execution remain important risks too.

Its approximately ₹9,823 crore net cash position provides room to invest, but new products still need to earn attractive returns.

Cipla's Q2 results are not evidence of a weak India business. They show how difficult it can be to replace a few unusually profitable medicines once competition or supply problems change their economics. The next two quarters will matter because the company needs to deliver on two promises at the same time: revive US sales and improve the amount of profit it makes from those sales. A recovery in revenue alone will not settle the investment debate.